{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:42:32Z","timestamp":1777614152150,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13370-8","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T06:18:59Z","timestamp":1735798739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictive marker for response to trifluridine\/tipiracil plus bevacizumab in metastatic colorectal cancer patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Toshiaki","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1266-2875","authenticated-orcid":false,"given":"Kunitoshi","family":"Shigeyasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hibiki","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Moriwake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Kayano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Matsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Michiue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminori","family":"Teraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Kashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Kakiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"issue":"6","key":"13370_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"13370_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74\u2013108.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"13370_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69\u201390.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"13370_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"13370_CR5","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, Takashima A, Yokota M, Makiyama A, Akazawa N, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 2023;329(15):1271\u201382.","journal-title":"JAMA"},{"issue":"18","key":"13370_CR6","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Papai Z, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388(18):1657\u201367.","journal-title":"N Engl J Med"},{"key":"13370_CR7","doi-asserted-by":"publisher","first-page":"goac035","DOI":"10.1093\/gastro\/goac035","volume":"10","author":"S Parmar","year":"2022","unstructured":"Parmar S, Easwaran H. Genetic and epigenetic dependencies in colorectal cancer development. Gastroenterol Rep (Oxf). 2022;10:goac035.","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"2","key":"13370_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nm.3043","volume":"19","author":"L Chen","year":"2013","unstructured":"Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, Liu M, Yuan YF, Fu L, Kong KL, et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med. 2013;19(2):209\u201316.","journal-title":"Nat Med"},{"issue":"5497","key":"13370_CR9","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1126\/science.290.5497.1765","volume":"290","author":"Q Wang","year":"2000","unstructured":"Wang Q, Khillan J, Gadue P, Nishikura K. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science. 2000;290(5497):1765\u20138.","journal-title":"Science"},{"issue":"6944","key":"13370_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature01709","volume":"424","author":"B Mangeat","year":"2003","unstructured":"Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003;424(6944):99\u2013103.","journal-title":"Nature"},{"key":"13370_CR11","doi-asserted-by":"crossref","unstructured":"Shigeyasu K, Okugawa Y, Toden S, Miyoshi J, Toiyama Y, Nagasaka T, Takahashi N, Kusunoki M, Takayama T, Yamada Y et al: AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. JCI Insight. 2018;3(12):e99976.","DOI":"10.1172\/jci.insight.99976"},{"key":"13370_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2018.12.009","volume":"444","author":"S Takeda","year":"2019","unstructured":"Takeda S, Shigeyasu K, Okugawa Y, Yoshida K, Mori Y, Yano S, Noma K, Umeda Y, Kondo Y, Kishimoto H, et al. Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer. Cancer Lett. 2019;444:127\u201335.","journal-title":"Cancer Lett"},{"issue":"1","key":"13370_CR13","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1038\/s41598-023-29397-z","volume":"13","author":"N Hata","year":"2023","unstructured":"Hata N, Shigeyasu K, Umeda Y, Yano S, Takeda S, Yoshida K, Fuji T, Yoshida R, Yasui K, Umeda H, et al. ADAR1 is a promising risk stratification biomarker of remnant liver recurrence after hepatic metastasectomy for colorectal cancer. Sci Rep. 2023;13(1):2078.","journal-title":"Sci Rep"},{"issue":"5","key":"13370_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3892\/mco.2020.2133","volume":"13","author":"M Cui","year":"2020","unstructured":"Cui M, Xu R, Yan B. A persistent high neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with colorectal cancer undergoing resection. Mol Clin Oncol. 2020;13(5):63.","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"13370_CR15","doi-asserted-by":"publisher","first-page":"13540","DOI":"10.1038\/s41598-022-17773-0","volume":"12","author":"Y Komatsu","year":"2022","unstructured":"Komatsu Y, Shigeyasu K, Yano S, Takeda S, Takahashi K, Hata N, Umeda H, Yoshida K, Mori Y, Yasui K, et al. RNA editing facilitates the enhanced production of neoantigens during the simultaneous administration of oxaliplatin and radiotherapy in colorectal cancer. Sci Rep. 2022;12(1):13540.","journal-title":"Sci Rep"},{"issue":"5","key":"13370_CR16","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.21873\/anticanres.14264","volume":"40","author":"R Tanaka","year":"2020","unstructured":"Tanaka R, Kimura K, Eguchi S, Tauchi J, Shibutani M, Shinkawa H, Ohira GO, Yamazoe S, Tanaka S, Amano R, et al. Preoperative neutrophil-to-lymphocyte ratio predicts tumor-infiltrating CD8(+) T cells in biliary tract cancer. Anticancer Res. 2020;40(5):2881\u20137.","journal-title":"Anticancer Res"},{"issue":"1","key":"13370_CR17","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1038\/s41467-023-38581-8","volume":"14","author":"TL Wong","year":"2023","unstructured":"Wong TL, Loh JJ, Lu S, Yan HHN, Siu HC, Xi R, Chan D, Kam MJF, Zhou L, Tong M, et al. ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer. Nat Commun. 2023;14(1):2861.","journal-title":"Nat Commun"},{"issue":"7957","key":"13370_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41586-023-05706-4","volume":"616","author":"C Martinez-Ruiz","year":"2023","unstructured":"Martinez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, Thol K, Jones TP, Veeriah S, Naceur-Lombardelli C, et al. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature. 2023;616(7957):543\u201352.","journal-title":"Nature"},{"issue":"1","key":"13370_CR19","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1038\/s41467-018-06405-9","volume":"9","author":"M Zhang","year":"2018","unstructured":"Zhang M, Fritsche J, Roszik J, Williams LJ, Peng X, Chiu Y, Tsou CC, Hoffgaard F, Goldfinger V, Schoor O, et al. RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat Commun. 2018;9(1):3919.","journal-title":"Nat Commun"},{"key":"13370_CR20","doi-asserted-by":"publisher","first-page":"593989","DOI":"10.3389\/fonc.2020.593989","volume":"10","author":"C Zhou","year":"2020","unstructured":"Zhou C, Wei Z, Zhang L, Yang Z, Liu Q. Systematically characterizing A-to-I RNA editing neoantigens in cancer. Front Oncol. 2020;10:593989.","journal-title":"Front Oncol"},{"issue":"3","key":"13370_CR21","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.5808\/GI.2019.17.3.e23","volume":"17","author":"J Park","year":"2019","unstructured":"Park J, Chung YJ. Identification of neoantigens derived from alternative splicing and RNA modification. Genomics Inform. 2019;17(3):e23.","journal-title":"Genomics Inform"},{"issue":"7","key":"13370_CR22","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","volume":"23","author":"C Antoniotti","year":"2022","unstructured":"Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23(7):876\u201387.","journal-title":"Lancet Oncol"},{"issue":"7914","key":"13370_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-022-04753-7","volume":"606","author":"T Zhang","year":"2022","unstructured":"Zhang T, Yin C, Fedorov A, Qiao L, Bao H, Beknazarov N, Wang S, Gautam A, Williams RM, Crawford JC, et al. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature. 2022;606(7914):594\u2013602.","journal-title":"Nature"},{"issue":"1","key":"13370_CR24","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1038\/s41467-023-39570-7","volume":"14","author":"C Tretter","year":"2023","unstructured":"Tretter C, de Andrade KN, Pecoraro M, Lange S, Seifert P, von Frankenberg C, Untch J, Zuleger G, Wilhelm M, Zolg DP, et al. Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification. Nat Commun. 2023;14(1):4632.","journal-title":"Nat Commun"},{"issue":"5","key":"13370_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3892\/mco.2021.2269","volume":"14","author":"T Nemoto","year":"2021","unstructured":"Nemoto T, Endo S, Isohata N, Takayanagi D, Nemoto D, Aizawa M, Utano K, Togashi K. Change in the neutrophil-to-lymphocyte ratio during chemotherapy may predict prognosis in patients with advanced or metastatic colorectal cancer. Mol Clin Oncol. 2021;14(5):107.","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"13370_CR26","doi-asserted-by":"publisher","first-page":"e741","DOI":"10.1016\/j.clcc.2018.08.002","volume":"17","author":"Y Sunakawa","year":"2018","unstructured":"Sunakawa Y, Yang D, Cao S, Zhang W, Moran M, Astrow SH, Hsiang J, Stephens C, Tsuji A, Takahashi T, et al. Immune-related genes to dominate Neutrophil-lymphocyte Ratio (NLR) associated with survival of cetuximab treatment in metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17(4):e741\u20139.","journal-title":"Clin Colorectal Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13370-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T07:03:05Z","timestamp":1735801385000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13370-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13370"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13370-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A written informed consent was obtained from each patient, and the current study was approved by the Ethics Committee of Okayama University Hospital (Approval Number: 1903-037).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}